Department of General Surgery, Kantonsspital Aarau, Aarau, Switzerland.
Chirurgie Aarau, Aarau, Switzerland.
BJS Open. 2021 Mar 5;5(2). doi: 10.1093/bjsopen/zraa027.
Antimicrobial prophylaxis (AMP) adjustment according to bodyweight to prevent surgical-site infections (SSI) is controversial. The impact of weight-adjusted AMP dosing on SSI rates was investigated here.
Results from a first study of patients undergoing visceral, vascular or trauma operations, and receiving standard AMP, enabled retrospective evaluation of the impact of bodyweight and BMI on SSI rates, and identification of patients eligible for weight-adjusted AMP. In a subsequent observational prospective study, patients weighing at least 80 kg were assigned to receive double-dose AMP. Risk factors for SSI, including ASA classification, duration and type of surgery, wound class, diabetes, weight in kilograms, BMI, age, and AMP dose, were evaluated in multivariable analysis.
In the first study (3508 patients), bodyweight and BMI significantly correlated with higher rates of all SSI subclasses (both P < 0.001). An 80-kg cut-off identified patients receiving single-dose AMP who were at higher risk of SSI. In the prospective study (2161 patients), 546 patients weighing 80 kg or more who received only single-dose AMP had higher rates of all SSI types than a group of 1615 who received double-dose AMP (odds ratio (OR) 4.40, 95 per cent c.i. 3.18 to 6.23; P < 0.001). In multivariable analysis including 5021 patients from both cohorts, bodyweight (OR 1.01, 1.00 to 1.02; P = 0.008), BMI (OR 1.01, 1.00 to 1.02; P = 0.007) and double-dose AMP (OR 0.33, 0.23 to 0.46; P < 0.001) among other variables were independently associated with SSI rates.
Double-dose AMP decreases SSI rates in patients weighing 80 kg or more.
根据体重调整抗菌预防(AMP)以预防手术部位感染(SSI)存在争议。本研究旨在探讨体重调整 AMP 剂量对 SSI 发生率的影响。
对接受标准 AMP 的内脏、血管或创伤手术患者的第一项研究结果进行回顾性评估,以评估体重和 BMI 对 SSI 发生率的影响,并确定符合体重调整 AMP 条件的患者。在随后的观察性前瞻性研究中,体重至少 80 公斤的患者被分配接受双倍剂量 AMP。多变量分析评估了 SSI 的危险因素,包括 ASA 分类、手术持续时间和类型、伤口分级、糖尿病、体重(公斤)、BMI、年龄和 AMP 剂量。
在第一项研究(3508 例患者)中,体重和 BMI 与所有 SSI 亚类的发生率显著相关(均 P<0.001)。80 公斤的截断值确定了接受单剂量 AMP 的患者发生 SSI 的风险更高。在前瞻性研究(2161 例患者)中,546 例体重 80 公斤或以上仅接受单剂量 AMP 的患者发生所有 SSI 类型的比例高于 1615 例接受双倍剂量 AMP 的患者(比值比 4.40,95%置信区间 3.18 至 6.23;P<0.001)。在包括两个队列的 5021 例患者的多变量分析中,体重(比值比 1.01,1.00 至 1.02;P=0.008)、BMI(比值比 1.01,1.00 至 1.02;P=0.007)和双倍剂量 AMP(比值比 0.33,0.23 至 0.46;P<0.001)与其他变量一起与 SSI 发生率独立相关。
体重 80 公斤或以上的患者接受双倍剂量 AMP 可降低 SSI 发生率。